Xu Wen, Le Yijun, Zhang Jianzhong
Department of Dermatology, Peking University People's Hospital, Beijing, China.
Musculoskeletal Tumor Center, Peking University People's Hospital, Beijing, China.
Front Oncol. 2023 Feb 27;13:981111. doi: 10.3389/fonc.2023.981111. eCollection 2023.
Sebaceous gland carcinoma (SGC) is a rare tumor for which there are currently no effective tools to predict patient outcomes. We analyzed the clinical and pathological prognostic risk factors of sebaceous carcinoma based on population data and created a nomogram of related risk factors, which can more accurately predict the 3-, 5-, and 10-year overall survival (OS) rates of patients.
SGC patients between 2004 and 2015 were collected from the Surveillance, Epidemiology, and End Results (SEER) database and randomly assigned to training and validation cohorts. Relevant risk factors were identified by univariate and multivariate COX hazards regression methods and combined to produce a correlation nomogram. The concordance index (C-index), the area under the receiver operating characteristic (AUC) curve, and calibration plots have demonstrated the predictive power of the nomogram. Decision curve analysis (DCA) was used to measure nomograms in clinical practice.
A total of 2844 eligible patients were randomly assigned to 70% of the training group (n=1990) and 30% of the validation group (n=854) in this study. The derived meaningful prognostic factors were applied to the establishment of the nomogram. The C-index for OS was 0.725 (95% CI: 0.706-0.741) in the training cohort and 0.710 (95% CI: 0.683-0.737) in the validation cohort. The AUC and calibration plots of 3-, 5-, and 10-year OS rates showed that the nomogram had good predictive power. DCA demonstrated that the nomogram constructed in this study could provide a clinical net benefit.
We created a novel nomogram of prognostic factors for SGC, which more accurately and comprehensively predicted 3-, 5-, and 10-year OS in SGC patients. This can help clinicians identify high-risk patients as early as possible, carry out personalized treatment, follow-up, and monitoring, and improve the survival rate of SGC patients.
皮脂腺癌(SGC)是一种罕见肿瘤,目前尚无有效工具来预测患者预后。我们基于人群数据分析了皮脂腺癌的临床和病理预后危险因素,并创建了相关危险因素的列线图,其能够更准确地预测患者的3年、5年和10年总生存率(OS)。
收集2004年至2015年期间来自监测、流行病学和最终结果(SEER)数据库的SGC患者,并将其随机分配到训练队列和验证队列。通过单因素和多因素COX风险回归方法确定相关危险因素,并将其组合以生成相关性列线图。一致性指数(C指数)、受试者操作特征(AUC)曲线下面积和校准图已证明列线图的预测能力。决策曲线分析(DCA)用于衡量列线图在临床实践中的作用。
本研究共将2844例符合条件的患者随机分配到70%的训练组(n = 1990)和30%的验证组(n = 854)。将得出的有意义的预后因素应用于列线图的建立。训练队列中OS的C指数为0.725(95%CI:0.706 - 0.741),验证队列中为0.710(95%CI:0.683 - 0.737)。3年、5年和10年OS率的AUC和校准图显示列线图具有良好的预测能力。DCA表明本研究构建的列线图可提供临床净效益。
我们创建了一种新型的SGC预后因素列线图,其能更准确、全面地预测SGC患者的3年、5年和10年OS。这有助于临床医生尽早识别高危患者,进行个性化治疗、随访和监测,并提高SGC患者的生存率。